Whole-body staging in breast cancer patients using combined MR-PET

• Conditions: C50; Malignant neoplasm of breast

• Registration Number: DRKS00005410
• Lead Sponsor: niversitätsklinikum Düsseldorf, Institut für Diagnostische und Interventionelle Radiologie

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2013-10-29
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: Female
• Target Recruitment: 276

Inclusion Criteria

female sex, newly diagnosed locally advanced therapy naive breast cancer Tumor stage T2-T4 or triple-negative carcinoma or molecular high-risk carcinoma, 18 years or older, in premenopausal women: negative pregnancy test, written consent

Exclusion Criteria

Diagnosis of another cancer type within the last 5 years (except: basalioma, in situ cervical cancer), contradictions to MRI, high grade renal insufficiency (GFR < 30 mg/dl), psychological disease or state, that disables the understanding of the study protocol, pregnancy and lactation period.

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Evaluation of the diagnostic accuracy of combined whole-body 18F-FDG-MR-PET for whole-body staging in breast cancer.

Secondary Outcome Measures

Name	Time	Method
Comparison of combined whole-body 18F-FDG-MR-PET and the diagnostic standard (according to the guideline: interdisziplinären S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms ) with regard to the diagnostic accuracy for whole-body tumor staging in breast cancer.